For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Keratoconus has an early stage treatment option: Corneal collagen cross-linking
+Print Archive
EYE HEALTH
Keratoconus has an early stage treatment option: Corneal collagen cross-linking
Wednesday 13 March 2019, 04:00 AM

Application of collagen cross-linking therapy with UVA light (right) for keratoconus
Until recently, there was no way to prevent progression of keratoconus, but collagen cross-linking has now become the standard of care to halt the condition, and the earlier it begins, the better the short and long-term outcomes
Key points
Progressive keratoconus affects young people and, in some cases, can lead to blindness in the affected eye.
Corneal transplant has been
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.